Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs

European venture firm Sofinnova Partners is expanding the reach of its Biovelocita accelerator beyond Italy to stretch across the greater continent. On the latest BioCentury This Week podcast, BioCentury’s editors discuss how Biovelocita became the largest life sciences accelerator in Europe. The editors also discuss Novo Nordisk"s latest addition to its obesity pipeline via a deal in China, and how the partnership reflects the state of cross-border dealmaking more broadly. And Washington Editor Steve Usdin assesses President Trump’s threat to impose 25% tariffs on pharmaceutical imports and provides an update on how FDA’s staff is navigating the policies of the new administration. Finally, Editor in Chief Simone Fishburn discusses BioCentury"s upcoming Grand Rounds meetings. View full story: https://www.biocentury.com/article/655438 00:00 - Introduction 02:25 - Sofinnova’s Pan-European Accelerator 08:27 - China Biotechs 14:59 - Trump Tariffs To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text